---
title: "Weekly Recap | 3SBIO -9.79%, hitting a fresh 52-week low"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306350384.md"
description: "3SBIO fell 9.79% this week to close at HK$12.71, underperforming the Hang Seng Index, which lost 5.65% over the same period. The stock started Monday at HK$14.08 and touched a weekly high of HK$14.15 before trending lower. It slid through Tuesday and Wednesday, then hit a fresh 52-week low of HK$12.48 on Thursday before settling at HK$12.71. Weekly amplitude came to 11.86%, and average daily volume was around 13.2m shares, roughly 21.7% below the 60-day median."
datetime: "2026-11-21T05:13:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306350384.md)
  - [en](https://longbridge.com/en/news/306350384.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306350384.md)
generator: "portal-rs"
---

# Weekly Recap | 3SBIO -9.79%, hitting a fresh 52-week low

## The Week

3SBIO fell 9.79% this week to close at HK$12.71, underperforming the Hang Seng Index, which lost 5.65% over the same period. The stock started Monday at HK$14.08 and touched a weekly high of HK$14.15 before trending lower. It slid through Tuesday and Wednesday, then hit a fresh 52-week low of HK$12.48 on Thursday before settling at HK$12.71. Weekly amplitude came to 11.86%, and average daily volume was around 13.2m shares, roughly 21.7% below the 60-day median.

## Key Events

There were no company-specific product, earnings or regulatory announcements this week. The news flow centred on sharp price moves and a sector-wide policy signal. 3SBIO dropped over 5% early on Monday, and on Thursday the stock hit a fresh 52-week low. The same day, Citi noted that the 2026 NRDL negotiation results had been released, with drugmakers describing the price cuts as mild and manageable. The timing of the negotiation disclosure overlapped with the week’s downward price action.

## Analyst Ratings

Fourteen institutions cover 3SBIO: nine rate it buy, four rate it overweight and one rates it hold. No institution rates it underweight or sell. The consensus rating is strong buy, with a consensus target price of HK$28.91, which sits about 127.5% above the latest close of HK$12.71. Target prices range from HK$17.07 to HK$37.65, pointing to wide dispersion. Within the biotechnology industry, 3SBIO ranks 7th out of 52 peers.

## The Week Ahead

3SBIO reports fiscal Q3 2026 results before the open on Wednesday, 25 November. After this week’s fresh 52-week low, the focus shifts to revenue and earnings trends rather than the price move itself. The market will also watch whether the NRDL pricing signal feeds into subsequent quarters.

## In Short

This week brought a fresh 52-week low, yet the analyst backdrop remains constructive: consensus rating is strong buy, and the consensus target price is more than double the spot. Valuation sits at a low level, with P/E around 3.36x and P/B near 1.01x. The latest session’s fund flow shows large orders and medium orders pointing in opposite directions. The next test is next week’s quarterly results and how the NRDL signal lands in practice.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [01530.HK](https://longbridge.com/en/quote/01530.HK.md)

## Related News & Research

- [Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable](https://longbridge.com/en/news/306083646.md)
- [UBS Keeps Their Buy Rating on 3SBio (TRSBF)](https://longbridge.com/en/news/303823090.md)
- [Tamil Nadu Newsprint and Papers' (NSE:TNPL) Profits Appear To Have Quality Issues](https://longbridge.com/en/news/306343812.md)
- [KNR Constructions' (NSE:KNRCON) Conservative Accounting Might Explain Soft Earnings](https://longbridge.com/en/news/306343335.md)
- [Nexus: Unlocks 1,116.67 Billion NEX for Investors and Team - Nov 2027](https://longbridge.com/en/news/306343574.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**